-
JCOG8504
第III相試験
進行・再発乳癌に対するAC(ADM+CPA）とMC(MMC+CPA)無作為化比較試験
-
JCOG8808
ランダム化第II相試験
進行乳癌の内分泌化学療法に関する比較試験
-
JCOG9006
第II相試験
乳癌に対する自家骨髄移植を併用した大量化学療法(第Ⅱ相試験)
-
JCOG9107
第II相試験
ホルモン感受性のない進行・再発乳がんに対するG-CSFを併用した高用量エピルビシン、サイクロフォスファマイド投与に関する臨床第Ⅱ相試験
-
JCOG9113
第I/II相試験
肝転移を有する進行・再発乳がんに対する動注化学療法の有効性に関するPhaseⅠ/Ⅱstudy
-
JCOG9208
第III相試験
腋窩リンパ節転移10個以上の乳がん症例に対する術後化学療法の臨床第Ⅲ相試験
-
JCOG9401
第III相試験
閉経後腋窩リンパ節転移1-9個の乳癌症例に対する術後補助療法に関する臨床第Ⅲ相試験-TAM療法 vs ACT療法による無作為比較試験-
-
JCOG9404
第III相試験
閉経前腋窩リンパ節転移1-9個の乳癌症例に対する術後補助療法に関する臨床第Ⅲ相試験-TUFT療法 vs ACT療法による無作為比較試験-
-
JCOG9503
第II相試験
進行再発乳癌に対するSalvage chemotherapyの第Ⅱ相臨床試験-MMC+VLB併用療法
-
JCOG9602
第I相試験
進行再発乳がん症例に対する自家造血幹細胞移植併用大量化学療法の臨床第Ⅰ相試験
-
JCOG9802
第III相試験
転移性乳がん症例を対象としたCA(シクロフォスファミド・アドリアマイシン)とDocetaxelの投与順位に関する無作為化比較臨床試験
-
Feasibility study
｢転移性乳がん症例を対象としたCA(シクロフォスファミド・アドリアマイシン)とDocetaxelの投与順位に関する無作為化比較臨床試験(JCOG9802/BC 4-CAD)｣におけるQuality-of-life(QOL)評価のFeasibility Study
-
JCOG0111
第III相試験
転移性乳がんのAnthracycline耐性症例に対するPaclitaxelの週1回と3週1回投与のランダム化比較試験
-
JCOG0306
第II相試験
腫瘍径2cm以上のⅠ-ⅢA期 原発乳がんに対する術前化学療法とそれに続く放射線照射の有効性･安全性試験
-
第III相試験
薬物療法非抵抗性Stage IV 乳癌に対する原発巣切除の意義（原発巣切除なしversus あり）に関するランダム化比較試験
-
JCOG8808
JCOG8808
Construction and Validation of a Practical Prognostic Index for Patients with Metastatic Breast Cancer
N Yamamoto, T Watanabe, N Katsumata, et al.
J Clin Oncol. 16: 2461-2408, 1998.
-
JCOG8808
JCOG8808
Patients’ understanding of their own disease and survival potential in patients with metastatic breast cancer. Breast Cancer Res Treat. 61: 145-150, 2000.
H Okamura, N Yamamoto, T Watanabe, et al
Breast Cancer Res Treat. 61: 145-150, 2000.
-
JCOG9107
JCOG9107
A Phase II Study of High-dose Epirubicin (EPI) plus Cyclophosphamide (CPA) with G-CSF for Breast Cancer Patients with Visceral Metastases or Hormone-independent Tumors: A Trial of the Japan Clinical Oncology Group.
S Takashima, T Saeki, I Adachi, et al.:
Jpn J Clin Oncol. 27(5): 325-330, 1997.
-
JCOG9113
JCOG9113
A phase I/II Study of Continuous Intra-arterial Chemotherapy Using an Implantable Reservoir for the Treatment of Liver Metastases from Breast Cancer: A Japan Clinical Oncology Group (JCOG) Study 9113
T Ikeda, I Adachi, S Takashima, et al.
Jpn J Clin Oncol. 29(1): 23-27, 1999.
-
JCOG9208
JCOG9208
Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer
Y Tokuda, T Tajima, M Narabayashi, et al.
Japan Clinical Oncology Group study, JCOG 9208. Cancer Sci. 99: 145-151, 2008.
-
JCOG9401
JCOG9401
Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)
T Shien, H Iwata, K Aogiet al.
Int J Clin Oncol. Jan 2014. [Epub ahead of print].
-
JCOG9404
JCOG9404
Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404.
T Shien, H Iwata, T Fukutomi, et al.
Cancer Chemother Pharmacol. 74(3): 603-609, 2014.
-
JCOG9802
JCOG9802
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan ClinicalOncology Group trial (JCOG9802).
N Katsumata, T Watanabe, H Minami, et al.
Ann Oncol. 20(7): 1210-1215, 2009.
-
JCOG0306
JCOG0306
Final results of a safety and efficacy trial of preoperative sequential chemo-radiation therapy for the nonsurgical treatment in early breast cancer: Japan Clinical Oncology Group Study JCOG0306.
H Mukai, T Watanabe, M Mitsumori, et al.
Oncology. 85(6): 336-341, 2013.
-
JCOG1017
JCOG1017
A Randomized Controlled Trial Comparing Primary Tumour Resection Plus Systemic Therapy With Systemic Therapy Alone in Metastatic Breast Cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
T Shien, K Nakamura, T Shibata, et al
Jpn J Clin Oncol. 42(10): 970-973, 2012.
-
JCOG1017
JCOG1017
Resection of the primary tumor in stage IV breast cancer
T Shien, H Doihara
World J Clin Oncol. 5(2): 82-85, 2014.
-
JCOG1017
JCOG1017
Significance of primary lesion resection in Stage IV breast cancer.
T Shien, H Iwata .
Jpn J Clin Oncol. 1;47(5):381-384, 2017.
-
JCOG1204
JCOG1204
Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204
T Hojo, N Masuda, T Mizutani, et al.
Jpn J Clin Oncol. 45(10): 983-986, 2015.
-
JCOG1505
JCOG1505
Current approach and future perspective for ductal carcinoma in situ of the breast.
C Kanbayashi, H Iwata.
Jpn J Clin Oncol. 9; 47:1-7, 2017.
-
JCOG1607
JCOG1607
A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study).
Shimomura A, Tamura K, Tanaka K, et al
Jpn J Clin Oncol. 2021 Jul 2:hyab101. doi: 10.1093/jjco/hyab101.
-
JCOG
JCOG
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
Tanaka K, Masuda N, Hayashi N etal.
Breast Cancer. 2021 Jul;28(4):896-903.
-
JCOG1709A
JCOG1709A
Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A).
Iwatani T, Hara F, Shien T et al.
Jpn J Clin Oncol. 2021 Mar 3;51(3):498-503.
-
JCOG1505
JCOG1505
Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study.
Tsuda H, Yoshida M, Akiyama F et al.
Jpn J Clin Oncol. 2021 Mar 3;51(3):434-443.
-
JCOG
JCOG
Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
Noguchi E, Shien T, Iwata H.
Jpn J Clin Oncol. 2021 Mar 3;51(3):321-332.
-
JCOG
JCOG
Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer.
Sagara Y, Mori M, Yamamoto S
Oncologist. 2021 Apr;26(4):e686-e693.
-
JCOG
JCOG
Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy.
Shigematsu H, Fujisawa T, Shien T et al.
Jpn J Clin Oncol. 2020 Jun 10;50(6):629-634.
-
JCOG
JCOG
Adjuvant and neoadjuvant therapy for breast cancer.
Shien T, Iwata H.
Jpn J Clin Oncol. 2020 Mar 9;50(3):225-229.
-
JCOG
JCOG
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
Niikura N, Shimomura A, Fukatsu Y et al.
Breast Cancer Res Treat. 2018 Jan;167(1):81-87.
-
JCOG
JCOG
TNM classification of malignant tumors (Breast Cancer Study Group).
Sawaki M, Shien T, Iwata H.
Jpn J Clin Oncol. 2019 Mar 1;49(3):228-231.
-
JCOG
JCOG
Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples.
Iwamoto T, Niikura N, Ogiya R et al.
Sci Rep. 2019 Sep 16;9(1):13343.
-
JCOG
JCOG
Current status of postmastectomy radiation therapy in T1-2 breast cancer with limited positive lymph nodes in Japan: Japan Clinical Oncology Group Survey.
Sasada S, Shien T, Iwata H.
Breast Cancer. 2018 Sep;25(5):626-627.
-
JCOG
JCOG
Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.
Ogiya R, Niikura N, Kumaki N et al.
Oncotarget. 2017 Oct 27;8(61):103671-103681.
-
JCOG
JCOG
The transition of breast cancer treatment and Japan Clinical Oncology Group research over two decades.
Iwata H.
Jpn J Clin Oncol. 2012 Jan;42(1):14-20.
